KLRC1 and neoplasm: Another reasonable approach is the blockade of programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1) and natural killer group protein 2A (NKG2A) signaling pathway using antibodies or small interfering RNA (siRNA) to prevent iNKT cell anergy induced by glycolipid antigen, α-galactosylceramide, and enhance anti-tumor activity in alcohol-induced tumor bearing mice [163,164].